XavierSee
2021-07-27
Nice
After Covid, BioNTech Has Its Sights Set on Malaria<blockquote>新冠疫情过后，BioNTech将目光投向了疟疾</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":809600385,"tweetId":"809600385","gmtCreate":1627362014147,"gmtModify":1633765706881,"author":{"id":3586581180889843,"idStr":"3586581180889843","authorId":3586581180889843,"authorIdStr":"3586581180889843","name":"XavierSee","avatar":"https://static.tigerbbs.com/eb0e623ff55f8e13ab98c063c20cfdb7","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/809600385","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","kind":"news","pubTimestamp":1627356038,"share":"https://www.laohu8.com/m/news/1153403036?lang=zh_CN&edition=full","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria<blockquote>新冠疫情过后，BioNTech将目光投向了疟疾</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p><p><blockquote>BioNTech作为一家备受尊敬（尽管有点不为人知）的生物技术公司进入2020年。一年多后，该公司因创造出最成功的冠状病毒疫苗之一而闻名于世，其股价上涨了150%，联合创始人Uğur Ş ahin现已跻身全球500强富豪之一。不算太寒酸。</blockquote></p><p> On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p><p><blockquote>周一，该公司宣布了下一个目标：独自开发一种疫苗来预防疟疾，疟疾是世界上最致命的疾病之一，也是疫苗生产商臭名昭著的谜。</blockquote></p><p> The Hardest Pathogen to Hack</p><p><blockquote>最难破解的病原体</blockquote></p><p> There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p><p><blockquote>目前只有一种获批的疟疾疫苗。葛兰素史克开发的Mosquirix在四年内只有39%的有效率。与此同时，2019年有2.29亿疟疾病例——其中94%在非洲——每年有40万人死于这种疾病，几乎都是非洲儿童。</blockquote></p><p> BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p><p><blockquote>BioNTech将使用信使核糖核酸(mRNA)开发疟疾候选疫苗，信使核糖核酸指导身体制造部分病毒以引发免疫反应。该公司还将在非洲的工厂生产和测试其他候选产品：</blockquote></p><p> <ul> <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li> <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li> </ul> \"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p><p><blockquote><ul><li>牛津大学今年推出了一种这样的候选药物，这是第一个达到世界卫生组织75%疗效目标的药物。在一项针对布基纳法索450名儿童的研究中，它预防了77%的病例，一项针对4800名儿童的试验正在计划中，以确认结果。</li><li>BioNTech的目标是明年准备好mRNA疟疾和结核病疫苗进行临床试验，但表示疟疾可能与癌症一样难以研究。该公司为早期开发设定了2000万至5000万欧元的基准。</li></ul>沙欣告诉记者：“这不会是一个本垒打。”<i>金融时报</i>“这是一种非常非常难破解的病原体。”BioNTech开发的任何疟疾疫苗都将在非营利基础上在非洲销售，该公司的目标是在一到两年内提供90%有效率的疫苗。</blockquote></p><p> <b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p><p><blockquote><b>侵入性和规避性：</b>疟疾是由一种复杂的寄生虫引起的，这种寄生虫可能会产生数千种抗原，并有许多逃避免疫系统的方法。与许多疾病不同，由于其复杂性，它有可能一次又一次地感染。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria<blockquote>新冠疫情过后，BioNTech将目光投向了疟疾</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria<blockquote>新冠疫情过后，BioNTech将目光投向了疟疾</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-07-27 11:20</span>\n</p>\n</h4>\n</header>\n<article>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p><p><blockquote>BioNTech作为一家备受尊敬（尽管有点不为人知）的生物技术公司进入2020年。一年多后，该公司因创造出最成功的冠状病毒疫苗之一而闻名于世，其股价上涨了150%，联合创始人Uğur Ş ahin现已跻身全球500强富豪之一。不算太寒酸。</blockquote></p><p> On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p><p><blockquote>周一，该公司宣布了下一个目标：独自开发一种疫苗来预防疟疾，疟疾是世界上最致命的疾病之一，也是疫苗生产商臭名昭著的谜。</blockquote></p><p> The Hardest Pathogen to Hack</p><p><blockquote>最难破解的病原体</blockquote></p><p> There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p><p><blockquote>目前只有一种获批的疟疾疫苗。葛兰素史克开发的Mosquirix在四年内只有39%的有效率。与此同时，2019年有2.29亿疟疾病例——其中94%在非洲——每年有40万人死于这种疾病，几乎都是非洲儿童。</blockquote></p><p> BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p><p><blockquote>BioNTech将使用信使核糖核酸(mRNA)开发疟疾候选疫苗，信使核糖核酸指导身体制造部分病毒以引发免疫反应。该公司还将在非洲的工厂生产和测试其他候选产品：</blockquote></p><p> <ul> <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li> <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li> </ul> \"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p><p><blockquote><ul><li>牛津大学今年推出了一种这样的候选药物，这是第一个达到世界卫生组织75%疗效目标的药物。在一项针对布基纳法索450名儿童的研究中，它预防了77%的病例，一项针对4800名儿童的试验正在计划中，以确认结果。</li><li>BioNTech的目标是明年准备好mRNA疟疾和结核病疫苗进行临床试验，但表示疟疾可能与癌症一样难以研究。该公司为早期开发设定了2000万至5000万欧元的基准。</li></ul>沙欣告诉记者：“这不会是一个本垒打。”<i>金融时报</i>“这是一种非常非常难破解的病原体。”BioNTech开发的任何疟疾疫苗都将在非营利基础上在非洲销售，该公司的目标是在一到两年内提供90%有效率的疫苗。</blockquote></p><p> <b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p><p><blockquote><b>侵入性和规避性：</b>疟疾是由一种复杂的寄生虫引起的，这种寄生虫可能会产生数千种抗原，并有许多逃避免疫系统的方法。与许多疾病不同，由于其复杂性，它有可能一次又一次地感染。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":289,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/809600385"}
精彩评论